Eli Lilly posts $23 billion quarter as volumes rise 60% and prices fall
Eli Lilly's quarterly revenue rose 48% year over year, with Mounjaro and Zepbound contributing about $14.9 billion. Shares slipped before the report.
- published on Newsmetry
- original source published
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner. connect the api →
what happened
According to TradingView, Eli Lilly reported quarterly revenue of $23.0 billion, up 48% from a year earlier. Volumes rose 60%, while realized prices fell 13%. Mounjaro and Zepbound together accounted for about $14.9 billion of sales.
The company also won market authorization in April 2026 for Foundayo, its oral GLP-1 therapy. Under Medicare's 2025 policy, Foundayo is among the GLP-1 drugs subject to a $50 copay.
The summary also cites Phase 1 data from ESMO 2026 for the company's FRα-targeting antibody-drug conjugate in platinum-sensitive ovarian cancer, showing an objective response rate of 79% and a disease control rate of 100%. Lilly shares fell about 1.7% in premarket trading ahead of the earnings release.
why it matters
Revenue growth alongside lower realized prices suggests pricing and access programs are becoming a key factor for profit. Traders were positioning around pricing impact before the report, so the market reaction largely reflects margin expectations.
market impact
Pharma sector and LLY: price pressure alongside rising volumes weighs on the company's margins and GLP-1 sentiment.
tags
instruments
sources
- Key facts: Eli Lilly posts $23B quarter; Foundayo approved, $50 copay — TradingView, 24 October 2026 at 07:00 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner.
get stories in real time ↗